Therefore, we show, for the first time, that CD90 is not only involved with malignant transformation in breast cancer cell lines, but is also correlated with metastasis and poor patient survival for the basal-like subtype, being considered as a promising new breast cancer marker to be targeted in future breast cancer therapy. This evidence concerns the gene THY1 and breast cancer.